BRPI0609779A2 - composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide - Google Patents

composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide Download PDF

Info

Publication number
BRPI0609779A2
BRPI0609779A2 BRPI0609779-0A BRPI0609779A BRPI0609779A2 BR PI0609779 A2 BRPI0609779 A2 BR PI0609779A2 BR PI0609779 A BRPI0609779 A BR PI0609779A BR PI0609779 A2 BRPI0609779 A2 BR PI0609779A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition according
lyothyronine
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0609779-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Martin Wade Beasley
David P Hause
Irwin Klein
Charles L Pamplin
David John Reynolds
Kevin H Sills
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BRPI0609779A2 publication Critical patent/BRPI0609779A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0609779-0A 2005-03-31 2006-03-31 composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide BRPI0609779A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66662105P 2005-03-31 2005-03-31
US60/666621 2005-03-31
PCT/US2006/012272 WO2006105482A2 (en) 2005-03-31 2006-03-31 Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same

Publications (1)

Publication Number Publication Date
BRPI0609779A2 true BRPI0609779A2 (pt) 2011-10-18

Family

ID=37054215

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0609779-0A BRPI0609779A2 (pt) 2005-03-31 2006-03-31 composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide

Country Status (11)

Country Link
US (1) US20060246133A1 (https=)
EP (1) EP1863446A2 (https=)
JP (1) JP2008534621A (https=)
KR (1) KR20070119714A (https=)
CN (1) CN101175477A (https=)
AU (1) AU2006230557A1 (https=)
BR (1) BRPI0609779A2 (https=)
CA (1) CA2603313A1 (https=)
IL (1) IL185723A0 (https=)
MX (1) MX2007011826A (https=)
WO (1) WO2006105482A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
WO2008057464A2 (en) * 2006-11-01 2008-05-15 King Pharmaceuticals Research And Development, Inc. Compositions and methods for improving the bioavailability of liothyronine
PL1958620T3 (pl) * 2007-02-16 2012-09-28 Csem Ct Suisse Delectronique Microtechnique Sa Rech Developpement Sposób weryfikacji
ITMI20112066A1 (it) * 2011-11-14 2013-05-15 Altergon Sa Preparazione farmaceutica orale monodose di ormoni tiroidei t3 e t4
MX2018013410A (es) * 2016-05-03 2019-06-06 Spectrix Therapeutics Llc Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma.
US10695309B2 (en) * 2017-03-31 2020-06-30 Western New England University Sustained-release liothyronine formulations, method of preparation and method of use thereof
US11964048B2 (en) * 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine
US20250262160A1 (en) * 2022-04-22 2025-08-21 Prolevi Bio Ab Compositions for modified release of active ingredients
CN115645361B (zh) * 2022-09-30 2023-11-21 天津市眼科医院 一种用于加强角膜生物力学性质的眼用制剂及t3的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
DE69224809T2 (de) * 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods

Also Published As

Publication number Publication date
MX2007011826A (es) 2007-11-22
CA2603313A1 (en) 2006-10-05
KR20070119714A (ko) 2007-12-20
CN101175477A (zh) 2008-05-07
AU2006230557A1 (en) 2006-10-05
US20060246133A1 (en) 2006-11-02
JP2008534621A (ja) 2008-08-28
IL185723A0 (en) 2008-01-06
EP1863446A2 (en) 2007-12-12
WO2006105482A3 (en) 2006-12-07
WO2006105482A2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP3662942B2 (ja) 持続性放出甲状腺作用性組成物
TWI241911B (en) Sustained release ranolazine formulations
MXPA02010347A (es) Composicion.
BR112014025907B1 (pt) Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento
BRPI0517227B1 (pt) comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
BRPI0621633A2 (pt) composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada
JP2021506944A (ja) 持続放出ミドドリン塩酸塩組成物及び使用方法
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
PT85128B (pt) Processo para a preparacao de composicoes farmaceuticas contendo, como ingrediente activo, 4-(1-metil-4-piperidilideno)-4h-benzo-{4,5}ciclohepta{1,2-b}tiofeno--10(9h)-ona
BRPI0609779A2 (pt) composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide
JP5561885B2 (ja) ミルタザピンの新しい配合物
US20230285342A1 (en) Compositions and methods
US20220362191A1 (en) Compositions and methods
US20180064669A1 (en) Compositions and methods of providing thyroid hormone or analogs thereof
MXPA04009906A (es) Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda.
CN120392682A (zh) 速释组合物
WO2025051298A1 (zh) 一种盐酸伊伐布雷定缓释片及其制备方法
AU2017261225B2 (en) Compositions and methods of providing thyroid hormone or analogs thereof
WO2019094292A1 (en) Compositions and methods of providing thyroid hormone of analogs thereof
Ostwal et al. Development and evaluation for tablet-in capsule of nefedipine and atenolol
EP4536182A1 (en) Phloroglucinol formulations and methods of use
TWI297609B (en) A new oral dosage containing desloratadine and pseudoephedrine hc1 or h2s04 drugs with immediate-release and controlled-release delivery.
WO2023106959A1 (ru) Фармацевтическая композиция, включающая мелатонин и дифенгидрамин или его фармацевтически приемлемую соль
RU2174391C1 (ru) Фармацевтическая композиция с антидепрессантной активностью

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.